🇺🇸 FDA
Pipeline program

Placebo A, NNC0487-0111, NNC0487-0111, NNC0487-0111, Placebo C tablets, NNC0487-0111, METFORMIN , NNC0487-0111, NNC0487-0111, NNC0487-0111, DAPAGLIFLOZIN , NNC0487-0111

NN9490-7678

Phase 2 small_molecule active

Quick answer

Placebo A, NNC0487-0111, NNC0487-0111, NNC0487-0111, Placebo C tablets, NNC0487-0111, METFORMIN , NNC0487-0111, NNC0487-0111, NNC0487-0111, DAPAGLIFLOZIN , NNC0487-0111 for Type 2 Diabetes is a Phase 2 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).

Program details

Company
Novo Nordisk A/S
Indication
Type 2 Diabetes
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials